How would muscle twitching start after ingesting 360 mg of pyridostigmine (Mestinon)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Muscle Twitching After Pyridostigmine Overdose

After ingesting 360 mg of pyridostigmine (Mestinon), muscle twitching would begin within minutes to an hour after ingestion, presenting as involuntary fasciculations that would progress from mild twitching to more severe muscle contractions if left untreated.

Mechanism of Action and Overdose Effects

Pyridostigmine is an acetylcholinesterase inhibitor that prevents the breakdown of acetylcholine at the neuromuscular junction. In overdose situations:

  • Pyridostigmine causes accumulation of acetylcholine in the synaptic cleft 1
  • This leads to overstimulation of both muscarinic and nicotinic receptors throughout the body 1
  • Nicotinic effects specifically cause muscle fasciculations (twitching) followed by weakness and potentially flaccid paralysis 1

Timeline of Symptom Development

Based on clinical evidence from overdose cases:

  • Initial symptoms develop rapidly, within minutes to 1 hour after ingestion 2, 3
  • Fasciculations (muscle twitching) are among the earliest nicotinic manifestations
  • Symptoms typically follow this progression:
    1. Initial twitching/fasciculations (nicotinic effect)
    2. Increased muscle weakness if exposure continues
    3. Potential progression to flaccid paralysis in severe cases 1

Clinical Presentation of Muscle Twitching

The muscle twitching from pyridostigmine overdose has specific characteristics:

  • Begins as fine, involuntary fasciculations visible under the skin
  • Often starts in smaller muscle groups and can become more widespread
  • May be accompanied by muscle cramps and weakness 4
  • Can affect any skeletal muscle but often more noticeable in face, neck, and extremities

Associated Symptoms

Pyridostigmine overdose of 360 mg would likely produce both nicotinic and muscarinic effects:

Nicotinic Effects (alongside twitching):

  • Muscle weakness
  • Muscle cramps
  • Potential respiratory muscle involvement in severe cases

Muscarinic Effects (concurrent with twitching):

  • Increased salivation
  • Nausea, vomiting, diarrhea
  • Abdominal cramps
  • Increased bronchial secretions
  • Miosis (pupil constriction)
  • Diaphoresis (excessive sweating) 4

Severity Based on Dosage

A 360 mg dose of pyridostigmine represents a significant overdose:

  • Normal therapeutic dosing for myasthenia gravis typically doesn't exceed 600 mg daily in divided doses 5
  • Previous case reports show that doses between 390-900 mg caused mild to moderate cholinergic symptoms 3
  • At 360 mg, the patient would likely experience moderate cholinergic toxicity with prominent fasciculations

Treatment Considerations

If a patient presents with muscle twitching after pyridostigmine overdose:

  1. Administer atropine to counteract muscarinic effects (1-8 mg as needed) 3
  2. Consider gastric emptying followed by activated charcoal if presenting early 3
  3. Monitor for respiratory compromise due to muscle weakness
  4. Benzodiazepines may help manage agitation or seizures 5

Important Caveats

  • The severity of symptoms doesn't always correlate with the degree of cholinesterase inhibition 3
  • Symptoms are typically self-limiting in healthy adults but can last up to 24 hours 3
  • Cardiac effects should be monitored, particularly in elderly patients 2
  • Central nervous system manifestations are generally minimal with pyridostigmine overdose 3

Pyridostigmine overdose is generally well-tolerated in young healthy adults, but requires prompt recognition and management to prevent progression to more severe symptoms.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pyridostigmine Suicidal Attempt in a Myasthenia Gravis Patient.

The American journal of case reports, 2019

Research

Acute pyridostigmine overdose: a report of nine cases.

Israel journal of medical sciences, 1991

Guideline

Antidotal Therapy and Supportive Care

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.